BR112023025616A2 - Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas - Google Patents

Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas

Info

Publication number
BR112023025616A2
BR112023025616A2 BR112023025616A BR112023025616A BR112023025616A2 BR 112023025616 A2 BR112023025616 A2 BR 112023025616A2 BR 112023025616 A BR112023025616 A BR 112023025616A BR 112023025616 A BR112023025616 A BR 112023025616A BR 112023025616 A2 BR112023025616 A2 BR 112023025616A2
Authority
BR
Brazil
Prior art keywords
klk2
fusion protein
nucleic acid
gpi
recombinant cells
Prior art date
Application number
BR112023025616A
Other languages
English (en)
Inventor
L Emanuel Stuart
J Rutkoski Thomas
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112023025616A2 publication Critical patent/BR112023025616A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21035—Tissue kallikrein (3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas. a presente invenção refere-se a um construto de ácido nucleico recombinante que codifica uma proteína de fusão de calicreína2. a proteína de fusão de calicreína-2 inclui uma primeira sequência de nucleotídeos que codifica a calicreína-2 (klk2), e uma segunda sequência de nucleotídeos que codifica uma sequência de ligação de glicosilfosfatidilinositol (gpi), onde a sequência de ligação de gpi que codifica a sequência de nucleotídeos é posicionada 3’ em relação à sequência de nucleotídeos que codifica klk2. também são revelados vetores, preparações de células e métodos de uso dos mesmos.
BR112023025616A 2021-06-10 2022-06-08 Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas BR112023025616A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163209019P 2021-06-10 2021-06-10
PCT/IB2022/055355 WO2022259190A1 (en) 2021-06-10 2022-06-08 Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Publications (1)

Publication Number Publication Date
BR112023025616A2 true BR112023025616A2 (pt) 2024-02-27

Family

ID=82358484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025616A BR112023025616A2 (pt) 2021-06-10 2022-06-08 Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas

Country Status (9)

Country Link
US (1) US20220403397A1 (pt)
EP (1) EP4352217A1 (pt)
KR (1) KR20240021211A (pt)
CN (1) CN117480253A (pt)
AU (1) AU2022291273A1 (pt)
BR (1) BR112023025616A2 (pt)
CA (1) CA3222756A1 (pt)
IL (1) IL309179A (pt)
WO (1) WO2022259190A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
RU2162342C2 (ru) 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
EP2315846A4 (en) * 2008-08-05 2011-11-30 Univ Rochester PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES

Also Published As

Publication number Publication date
IL309179A (en) 2024-02-01
EP4352217A1 (en) 2024-04-17
CN117480253A (zh) 2024-01-30
CA3222756A1 (en) 2022-12-15
US20220403397A1 (en) 2022-12-22
AU2022291273A1 (en) 2024-01-25
KR20240021211A (ko) 2024-02-16
WO2022259190A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
ES2662402T3 (es) Neurotoxinas recombinantes de Clostridium botulinum
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
NO20020861L (no) Nye B7-4-molekyler og anvendelser derav
BR9914777A (pt) Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
NO953571L (no) T-celle-epitoper av vanlig raigress-pollen allergen
Chang et al. Proteolytic degradation of calf thymus terminal deoxynucleotidyl transferase.
BR112023004040A2 (pt) Mutante de il-2 e sua aplicação
BR112023001500A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno hla-g e usos dos mesmos
BR112023025616A2 (pt) Codificação de ácido nucleico para proteína de fusão klk2-gpi, células recombinantes e usos das mesmas
BR112023003526A2 (pt) Proteínas de fusão de coronavírus imunogênicos e métodos relacionados
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
BR112018076674A2 (pt) proteína de fusão entre o fator de viabilidade do cone derivado de bastonetes de forma curta e um peptídeo hidrofílico
MX2022003149A (es) Proteinas heterodimericas.
BR112021019032A2 (pt) Vetores de fator h e usos dos mesmos
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
BR112022026248A2 (pt) Conjugados de citocinas
Boulton et al. Abnormal human myoglobin: 53 (D4) glutamic acid→ lysine
AR124246A1 (es) Polipéptidos de interleucina-2 mutante dependientes del ph
BR112023002578A2 (pt) Variantes de fitase e polinucleotídeos codificando as mesmas
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes